Newspaper Advertisement for the Financial Result as on 31 March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aspira Pathlab & Diagnostics has published its audited financial results for FY2026 ended March 31, 2026. Total income from operations grew 13.6% to ₹2,498.20 lakhs from ₹2,199.90 lakhs in FY25. However, the company swung to a net loss of ₹68.91 lakhs compared to a net profit of ₹207.26 lakhs in the previous year. Q4 FY26 also reported a loss of ₹68.91 lakhs. Earnings per share turned negative at ₹-0.67 for FY26 versus ₹2.01 in FY25. The results were reviewed by the Audit Committee and approved by the Board of Directors on May 23, 2026, and published in newspapers on May 25, 2026 as per SEBI LODR regulations.
The shift from profit to loss despite revenue growth signals deteriorating profitability, likely due to increased costs or operating expenses. This negative earnings surprise could weigh on the stock price in the near term unless management provides clarification on cost control measures.